P574 Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023)

• Record Type: Journal Article
• Authors: Siegmund, B; Ryan, R; Abreu, M T; Vermeire, S; Dotan, I; Goetsch, M; Crosby, C; Woolcott, J; Komori, H K; Danese, S
• Is Part Of: Journal of Crohn's and colitis. Volume 17(2023)Supplement 1
• Page Start: i700
• Page End: i701
• Publication Date: 2023-01-30
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjac190.0704
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1, 4, 5 modulator (S1P1, 4, 5 ) in development for the treatment of moderately to severely active ulcerative colitis (UC). To better understand how etrasimod reduces inflammation and induces clinical remission, the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials included a per protocol exploratory analysis of peripheral blood inflammatory proteomics, the results of which are presented here. Methods: In ELEVATE UC 52 (NCT03945188) and ELEVATE UC 12 (NCT03996369), patients (16-80 years) with moderately to severely active UC were randomised 2:1 to once-daily etrasimod 2 mg or placebo (PBO). Plasma was collected at baseline and week 12 for both trials and week 52 for ELEVATE UC 52. Characterization of plasma inflammatory protein abundance and changes in abundance over time were assessed by proximity extension assay using the Olink Target 96 Inflammation panel. Normalized protein expression and change from baseline by visit were summarized by descriptive statistics; fold changes in Olink measurements were expressed as log2. Results: Plasma samples were collected and analysed from 238 patients in ELEVATE UC 52 (162 etrasimod, 76 PBO) and 163 patients in ELEVATE UC 12 (108 etrasimod, 55 PBO). While no meaningful changes in protein biomarkers were observed over time in PBO-treated patients, factors modulated by etrasimod included those associated with tissue remodelling (MMP-1, MMP-10), T-cell response (CD5, CD6, CD8A, TNFRSF9), chemotaxis (CCL11, CCL19, CCL28, CX3CL1), and pleiotropic cytokine response (IL-7, IL-17A, IL-10, OSM), with a high degree of overlap and consistency in trends between the two trials (Figure 1). Etrasimod induced statistically significant reductions in circulating inflammatory proteins including IL-17A and OSM at week 12, and these remained decreased at week 52. Decreases in IL-17A and OSM at weeks 12 and 52 correlated with efficacy outcome measures across various clinical subgroups in responders vs nonresponders (Table 1). Conclusion: In this per protocol exploratory analysis of two independent phase 3 randomised controlled trials, etrasimod induced consistent, statistically significant changes in circulating inflammatory proteins involved in tissue remodelling, T-cell response, chemotaxis, and cytokine response, including IL-17A and OSM. The reduction in activated immune cells in the peripheral blood of responders suggests etrasimod induces a reduction in inflammation that could contribute to remission.